Compositions and methods using anti-CS1 antibodies to treat...

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S138100, C435S375000

Reexamination Certificate

active

07842293

ABSTRACT:
The present disclosure provides methods for treating multiple myeloma comprising administering to a subject with multiple myeloma the anti-CS1 antibody HuLuc63 in combination with dexamethasone and, optionally, thalidomide.

REFERENCES:
patent: 2005/0025763 (2005-02-01), Williams
patent: 2006/0024296 (2006-02-01), Williams
patent: 2005/102387 (2005-11-01), None
patent: 2008/019376 (2008-02-01), None
patent: 2008/019378 (2008-02-01), None
patent: 2008/019379 (2008-02-01), None
Yan et al. (Can. Res. 66(4):2305-2313 (2006).
Koskela et al. (Leuk. Lymphoma 45(4):749-754 (2004) Abtract.
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
ATCC search for Luc63 antibody (pp. 1-3; May 11, 2009).
Richardson et al., “A Phase 2 study of Bortezomib in relapsed,refractory myeloma,” N Engl J Med, 348:2609-2617 (Jun. 2003).
Kumar and Rajkumar, “Thalidomide and lenalidomide in the treatment of multiple myeloma,” European J Cancer, 42(2006):1612-1622, (Jul. 2006).
Tai et al., “Killing of drug-sensitive and resistant myeloma cells and disruption of their bone marrow stromal interaction by HuLuc63, a novel humanized anti-CS1 monoclonal antibody,” Blood (ASH Annual Meeting Abstracts) 2006:108: Abstract 3470 (2006).
Richardson et al., “Immunomodulatory drug CC-5013 overcomes drug resistance and is well-tolerated in patients with relapsed multiple myeloma,” Blood, 100(9):3063-3067 (Nov. 2002).
International Search Report and Written Opinion for PCT Application No. PCT/US2007/075404, dated Feb. 2, 2008.
International Search Report and Written Opinion for PCT Application No. PCT/US2007/075403, dated Jan. 16, 2008.
Tai et al., “Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.” Blood, Oct. 9, 2007; [Epub ahead of print].
Afar et al., “Anti-myeloma activity of HuLuc63 alone and in combination with bortezomib.” Haematologica 92 (6) s2:146, 2007. (Abstract PO-530).
Rice et al., “HuLuc63 in Combination Regimens with Conventional and Targeted Therapies Has Additive and Synergistic Anti-Tumor Activity in Pre-Clinical Models of Myeloma.” Blood (ASH Annual Meeting Abstracts), Nov. 2007; 110:2517.
Sonneveld et al., “Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment” Eur J Cancer. Jan. 2003;39(1):9-18.
Jagannath S., “Treatment of myeloma in patients not eligible for transplantation.” Curr Treat Options Oncol. May 2005;6(3):241-53.
Bruno et al., “New drugs for treatment of multiple myeloma.” Lancet Oncol. Jul. 2004;5(7):430-42.
Lee et al., “DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.” J Clin Oncol. Jul. 15, 2003;21(14):2732-9.
Boles et al., “Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily.” Immunogenetics. 2001;52(3-4):302-7.
International Search Report and Written Opinion for PCT Application No. PCT/US2007/075401, dated May 15, 2008.
Anderson, Kenneth C., Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and Differences,Seminars in Hematology, vol. 42, pp. S3-S8 (2005).
Bray et al., “Studies on the Mechanism of Human Natural Killer Cell-Mediated Cytolysis,”Cellular Immunology, vol. 78, pp. 100-113 (1983).
Cavo et al., “Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma,”Blood, vol. 106, pp. 35-39 (2005).
Liu et al., “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells,”Proc. Natl. Acad. Sci., vol. 84, pp. 3439-3443 (1987).
Piccolella et al., Effects of Dexamethasone on Human Natural Killer Cell Cytotoxicity, Interferon Production, and Interleukin-2 Receptor Expression Induced by Microbial Antigens,Infection and Immunity, vol. 51, No. 2, pp. 712-714 (1986).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compositions and methods using anti-CS1 antibodies to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods using anti-CS1 antibodies to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods using anti-CS1 antibodies to treat... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4227449

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.